To compare the proportion of patients in remission and low disease activity (LDA) between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

To evaluate the diagnostic yield of whole-exome sequencing (WES) vs targeted gene panel (TGP) testing in patients evaluated for autoinflammation at the Great Ormond Street Hospital Autoinflammation Centre of Excellence.

The aim of this study was to identify robust predictive markers which may help personalize tapering protocols, minimizing flare risk while optimizing long-term disease management in RA patients.

To compare the severity at diagnosis and disease activity during follow-up between juvenile (jDM) and adult-onset (aDM) dermatomyositis.

We aimed to evaluate the effects of GLP-1 receptor agonists (GLP-1RA) on symptom burden and opioid use in patients with fibromyalgia using real-world data.

There are several pressing reasons to re-examine shingles and strategies for its prevention through vaccination. Firstly, the UK has recently recommended the introduction of a national childhood varicella vaccination programme, and this may impact the epidemiology of shingles. Secondly, treatments for immune-mediated inflammatory diseases are increasingly targeting immunological pathways essential for antiviral defence. Thirdly, we now have access to a highly efficacious shingles vaccine. This review article will explore each of these developments in a way that is globally relevant, incorporating international recommendations.

People with SSc report pain from multiple sources. Objectives were to develop a tool to map sources of pain in SSc, determine characteristics of pain from different sources and understand pain management experiences.

The development of inflammatory arthritis after bariatric surgery has been sporadically reported, but systematic clinical and imaging descriptions remain limited. Understanding these postoperative inflammatory patterns is crucial, and this study examines the emergence and characteristics of spondyloarthritis following bariatric procedures.

Clinical trials aimed at preventing rheumatoid arthritis in individuals at risk have had variable results. The long-term outcomes of disease interception, however, are not known. We aimed to examine the long-term effect of therapeutic intervention, with emphasis on efficacy and safety.

Despite growing evidence supporting the benefits of physical activity in patients with rheumatic and musculoskeletal diseases (RMDs), both clinicians and patients often remain cautious-particularly regarding higher intensities. Although exercise is universally recommended in international guidelines for these populations, it is frequently accompanied by warnings to engage only in moderate-intensity training. The primary objective of this systematic review was to examine the effectiveness and safety of high-intensity, land-based exercise in patients with inflammatory rheumatic conditions, compared with usual care, no intervention, or low-intensity exercise. We aimed to determine whether high-intensity exercise leads to an increase in disease activity, pain intensity, or impairment of function.

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex pain mechanisms that extend beyond inflammation. Although inflammatory nociceptive pain - primarily mediated by pro-inflammatory cytokines - represents the classic pathway and therapeutic target, many patients continue to experience pain despite suppression of inflammation. This residual pain often reflects non-inflammatory processes, including nociplastic and neuropathic pain. Central sensitization, a key mechanism of nociplastic pain, contributes to pain amplification and poor response to treatment. Fibromyalgia, considered the typical phenotype of nociplastic pain, can co-occur with axSpA and is associated with increased symptom burden and reduced efficacy of anti-inflammatory therapies. Neuropathic pain, albeit less common, can result from structural complications and requires targeted therapeutic approaches. In addition, biological sex differences further influence pain perception and treatment outcomes: female patients report more widespread pain, show higher rates of central sensitization and have a worse response to biologic therapies than male patients. Current treatment paradigms are effective for inflammation-driven symptoms but often fail to address the broader spectrum of pain phenotypes in axSpA. Future work should include the development of biomarkers to differentiate pain mechanisms, the refinement of assessment tools and the evaluation of multimodal therapies that target both inflammation and pain processes. This evolving understanding necessitates a shift from an inflammation-centric to a mechanism-informed approach to pain management in axSpA.

To investigate the relationship between maternal disease, anti-rheumatic treatment, autoantibody levels and foetal atrioventricular (AV) conduction.

Rheumatic and musculoskeletal diseases (RMDs) profoundly affect health-related quality of life (HRQoL), imposing a significant distinct burden on physical and mental well-being. Given the high prevalence and long-term disability associated with RMDs, understanding their impact is essential for informing public health priorities. This study aims to delineate the multifaceted impact of RMDs on HRQoL across diverse disease categories and examine how the impact on HRQoL varies by diagnosis and time since diagnosis.

Rheumatoid arthritis (RA) is a systemic inflammatory disorder associated with a significantly increased risk of cardiovascular events. This study aims to assess the prevalence of coronary artery disease (CAD) and its associated risk factors among Palestinian patients with RA, a population for which this data has been lacking.

To conduct data-driven sensitivity analyses to evaluate whether refined definitions of childhood-onset systemic lupus erythematosus (cSLE) treat-to-target goals provide better protection against moderate-severe flares and new damage, compared with original consensus-derived targets.

Type I IFNs (IFN-I) are central to pathogenesis and monitoring of SLE, yet clinically accessible biomarkers remain limited. Building on prior validation of membrane-bound SIGLEC-1 (mbSIGLEC-1), we conducted a proof-of-concept study to evaluate soluble SIGLEC-1 (sSIGLEC-1) as a useful IFN-I biomarker in SLE.